» Articles » PMID: 29205907

Prevalence, Treatment Patterns and Control Rates of Metabolic Syndrome in a Chinese Diabetic Population: China Cardiometabolic Registries 3B Study

Overview
Specialty Endocrinology
Date 2017 Dec 6
PMID 29205907
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/introduction: To investigate the prevalence and risk factors of metabolic syndrome (MetS) in Chinese type 2 diabetes mellitus patients, and assess the effect of MetS on the treatment patterns and blood glucose, blood pressure and blood lipids goal achievements.

Materials And Methods: Data from 25,454 type 2 diabetes mellitus patients including demographic data, anthropometric measurements, treatment patterns, and blood glucose and lipid profiles were retrospectively analyzed.

Results: Using modified Adult Treatment Panel III MetS criteria, the prevalence of MetS was 57.4% in type 2 diabetes mellitus patients. Multivariable logistic regression analysis showed that type 2 diabetes mellitus patients, who also fulfilled the criteria for MetS, tended to be women, living in the northeast, with a diabetes duration ≥5 years and leading a sedentary lifestyle. Most MetS (53.4%) and non-MetS (57%) diabetes patients received oral hypoglycemic drugs. Insulin or insulin combination therapies were more applied in MetS (37.5%) than in non-MetS (33.1%) diabetes patients, and the percentages of MetS diabetes patients receiving antihypertensive and lipid-modulating drugs were 52.9% and 28.2% vs 38.3% and 19.3% of the non-MetS diabetes patients. Just 37.5%, 15.6% and 32.9% of the MetS diabetes patients vs 54.6%, 45.6% and 40.4% of the non-MetS diabetes patients achieved the individual target goals for control of blood glucose (glycosylated hemoglobin <7%), blood pressure (systolic blood pressure <130 mmHg, diastolic blood pressure <80 mmHg) and blood lipids (total cholesterol <4.5 mmol/L), whereas just 2.1% achieved all three target goals.

Conclusions: MetS with a high prevalence in Chinese type 2 diabetes mellitus patients is associated with poor blood glucose, blood pressure and blood lipids control rate.

Citing Articles

Increasing Influenza Vaccination Rates among Patients with Type 2 Diabetes Mellitus in Chongqing, China: A Cross-Sectional Analysis Using Behavioral and Social Drivers Tools.

Li Z, Feng L, Long J, Xiong Y, Li T, Jiang B Vaccines (Basel). 2024; 12(8).

PMID: 39204024 PMC: 11360589. DOI: 10.3390/vaccines12080898.


Prevalence and co-prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross-sectional, multicenter, retrospective, observational study based on 3B study database.

Ji Q, Chai S, Zhang R, Li J, Zheng Y, Rajpathak S Front Endocrinol (Lausanne). 2024; 15:1362433.

PMID: 38919489 PMC: 11196810. DOI: 10.3389/fendo.2024.1362433.


Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio is a more powerful marker than TyG index for predicting metabolic syndrome in patients with type 2 diabetes mellitus.

Gong S, Gan S, Zhang Y, Zhou H, Zhou Q Front Endocrinol (Lausanne). 2023; 14:1248614.

PMID: 37854188 PMC: 10579940. DOI: 10.3389/fendo.2023.1248614.


Metabolic Syndrome in Patients With Diabetes Mellitus.

Essafi M, Bouabdellaoui L, Aynaou H, Salhi H, El Ouahabi H Cureus. 2022; 14(4):e24469.

PMID: 35637809 PMC: 9132124. DOI: 10.7759/cureus.24469.


Long-Term Effect of Zhenzhu Tiaozhi Capsule (FTZ) on Hyperlipidemia: 2-Year Results from a Retrospective Study Using Electronic Medical Records.

Huang X, Zhan H, Yang J, Peng L, Piao S, Wang L Evid Based Complement Alternat Med. 2021; 2021:6264414.

PMID: 34707672 PMC: 8545570. DOI: 10.1155/2021/6264414.


References
1.
Xu S, Sun F, Xu W, Jiao K, Shi B, Xie X . Simultaneous control of blood glucose, blood pressure, and lipid among drug-treated Type 2 diabetes patients from Shaanxi province, North-Western China: A multicenter study. Niger J Clin Pract. 2016; 19(6):784-792. DOI: 10.4103/1119-3077.181359. View

2.
Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C . Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013; 126(10):925.e11-22. DOI: 10.1016/j.amjmed.2013.02.035. View

3.
Pan C, Han P, Ji L, Ji Q, Lu J, Lin J . Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study. J Diabetes. 2014; 7(2):222-30. DOI: 10.1111/1753-0407.12179. View

4.
Wilson P, Kannel W, Silbershatz H, DAgostino R . Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999; 159(10):1104-9. DOI: 10.1001/archinte.159.10.1104. View

5.
Ford E, Giles W, Dietz W . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-9. DOI: 10.1001/jama.287.3.356. View